TOP > 外国特許検索 > HAIR-GROWTH PROMOTING COMPOSITION AND USAGE THEREOF

HAIR-GROWTH PROMOTING COMPOSITION AND USAGE THEREOF

外国特許コード F170009093
整理番号 (S2016-0059-N0)
掲載日 2017年5月30日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2016JP080815
国際公開番号 WO 2017069113
国際出願日 平成28年10月18日(2016.10.18)
国際公開日 平成29年4月27日(2017.4.27)
優先権データ
  • 特願2015-205999 (2015.10.20) JP
発明の名称 (英語) HAIR-GROWTH PROMOTING COMPOSITION AND USAGE THEREOF
発明の概要(英語) The present invention relates to providing a new hair-growth or hair-restoration promoting composition or a composition that prevents hair loss. More specifically, provided is a composition containing an iNOS inhibitor as an active ingredient. The present invention achieves an advantageous effect of hair growth or hair restoration by injecting the composition containing the iNOS inhibitor as the active ingredient into a mammal. The iNOS inhibitor used may be a low-molecular compound, an antibody, or into a nucleic acid medicine, such as an antisense oligo or siRNA. Also provided is a method for screening effective substances for promoting hair growth or hair restoration or for preventing hair loss.
従来技術、競合技術の概要(英語) BACKGROUND ART
Is generally the stimulation of hair growth, growth phase (anagen), catagen, rest (telogen) (non-patent document 1) classified into. In the case of human hair, then the growth period after 2-7 years, catagen, telogen phase through, the hair loss.
As the main function of the hair, trauma to provide protection from direct sunlight, and the like to prevent loss of body temperature, hair, mediate important social and communication, decrease the amount of the hair may result in the decrease of the QOL of people.
The cause of alopecia, male pattern alopecia, seborrheic alopecia, senile alopecia, alopecia areata, alopecia results from the administration of an anticancer drug, scarring alopecia, alopecia or the like occurs after birth can be classified as a post-partum. However, these hair loss is a measure for, at the moment it is not well-established.
The current, major pharmaceutical accepted as hair growth, hair growth agents include, minoxidil and finasteride is. Minoxidil is, initially, the main working vasodilation orally as a therapeutic agent for hypertension is medication developed, hypertension therapeutic agent to a patient undergoing treatment was adapted, and dilates the blood vessels, such as hirsutism is promotes the regeneration of hair was observed, the external preparation of the hair again as medical developed pharmaceutical product. Minoxidil K ATP is sensitive to vasodilation via activation of the channel. Is the primary function of the minoxidil, the initial growth phase of hair follicles from the telogen phase shift to the prompt to promote hair growth, hair growth in hair follicles to grow thick hair, and is considered to be such as to. DHT (dihydrotestosterone) bonding to the receptor of the sebaceous gland, an effect to inhibit the growth of hair. Finasteride is, the male hormone testosterone DHT is an enzyme that converts 2 to inhibit 5 - α-reductase, acts by suppressing the generation of DHT. Male sex hormones of benign prostate hyperplasia caused by a therapeutic agent for the treatment of male pattern alopecia (AGA) have been developed to apply to a pharmaceutical product.
These agents are presently commercially available but, to measures against hair loss, more effective pharmaceutical is still demanded.
Nitric oxide synthase (NOS, EC1.14.13.39) is, nitric oxide and nitrogen oxide (NO) is an enzyme involved in the synthesis. Is always constant in the presence of an intracellular NOS of constitutive NOS (cNOS) and, due to stress-induced inflammation NOS (iNOS, NOS2) classified, is further cNOS, (NOS1) of the neuronal eNOS nNOS (NOS3) of the vascular endothelium are classified (non-patent document 2). Is iNOS, known as an inflammatory stimulus such as lipopolysaccharide (LPS) induced by the, immune system, cardiovascular system, such as expressed in the lung. Is iNOS, defense against a pathogen known to be involved. Heretofore, iNOS inhibitors, the use of anti-inflammatory drugs or as anti-cancer agents, such as for the purpose of treating sepsis have been developed, including cosmetic supplements or cosmetics, to the development of therapeutically effective agents not yet provided.
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • NATIONAL UNIVERSITY CORPORATION TOKYO MEDICAL AND DENTAL UNIVERSITY
  • 発明者(英語)
  • SHINOZAKI, Shohei
  • SHIMOKADO, Kentaro
国際特許分類(IPC)
指定国 National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DJ DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JP KE KG KN KP KR KW KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG
ライセンスをご希望の方、特許の内容に興味を持たれた方は、下記問合せ先にご相談下さい。

PAGE TOP

close
close
close
close
close
close